Shalibhadra Finance Limited (BOM:511754)

CTI BioPharma Cash Flow Statement

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Net Income	160	119.7	83.81	60.2	35.15
Depreciation & Amortization	0.9	0.69	0.55	0.5	0.54
Loss (Gain) From Sale of Investments	-14.3	-	-	-	-
Change in Accounts Payable	4.1	3.42	1.84	8.4	-7.7
Change in Other Net Operating Assets	-0.9	-1.94	-0.2	-1.2	-0.29
Other Operating Activities	-2.5	-	-0	0.1	-
Operating Cash Flow	-269.9	25.44	-45.64	18.5	73.89
Operating Cash Flow Growth	-	-	-	-74.96%	1563.39%
Capital Expenditures	-8.69	-1.44	-2.49	-0.2	-2.05
Investment in Securities	-106.7	-	-	-	15.12
Other Investing Activities	11.39	-20.95	-17.75	-6.1	7.85
Investing Cash Flow	-104	-22.39	-20.24	-6.3	20.92
Short-Term Debt Issued	-	103.5	-	-	-
Long-Term Debt Issued	-	-	26.85	-	25.76
Total Debt Issued	-	103.5	26.85	-	25.76
Short-Term Debt Repaid	-27.1	-	-42.97	-47	-160.82
Long-Term Debt Repaid	-177.6	-75.02	-	-10.3	-
Total Debt Repaid	-204.7	-75.02	-42.97	-57.3	-160.82
Net Debt Issued (Repaid)	-204.7	28.48	-16.13	-57.3	-135.06
Common Dividends Paid	-8.4	-6.27	-4	-	-
Preferred Dividends Paid	-	-	-	-2.5	-
Total Dividends Paid	-8.4	-6.27	-4	-2.5	-
Other Financing Activities	455.7	72.47	126.04	66.1	-
Financing Cash Flow	242.6	94.67	105.91	6.3	-135.06
Net Cash Flow	-131.3	97.73	40.03	18.5	-40.25
Free Cash Flow	-278.59	24	-48.12	18.3	71.84
Free Cash Flow Growth	-	-	-	-74.53%	2041.34%
Free Cash Flow Margin	-89.29%	9.56%	-24.50%	12.41%	59.64%
Free Cash Flow Per Share	-7.53	0.86	-1.94	0.91	3.59
Cash Income Tax Paid	48.6	41.3	29.21	21.3	14.76

Source: S&P Global Market Intelligence. Financial Services template. Financial Sources.